Intrinsic stability of the antiviral drug umifenovir by stress testing and DFT studies.


Journal

Journal of pharmaceutical and biomedical analysis
ISSN: 1873-264X
Titre abrégé: J Pharm Biomed Anal
Pays: England
ID NLM: 8309336

Informations de publication

Date de publication:
20 Mar 2021
Historique:
received: 30 11 2020
revised: 20 01 2021
accepted: 24 01 2021
pubmed: 8 2 2021
medline: 22 6 2021
entrez: 7 2 2021
Statut: ppublish

Résumé

Umifenovir is an antiviral drug approved in China and Russia for the treatment of influenza. The available dosage form consists of capsules marketed under the brand name Arbidol®. Due to its broad spectrum, umifenovir may also be used in other viral contexts, alone or combined with other antiviral drugs. Although knowledge of umifenovir intrinsic stability may be useful for any potential development of other pharmaceutical forms for other routes of administration and for quality risk management, no data regarding this matter is available to date. In this study, the exploration of the molecule's behaviour under hydrolytic, oxidative and photolytic conditions was carried out experimentally and supported by density functional theory (DFT) studies. It comes out that umifenovir is sensitive to these stress conditions giving rise to 6 structurally characterized degradation products. The one-electron oxidation process produced on the sulphur atom is probably the main cause of umifenovir degradation with reference to the structures of the degradation products formed and the DFT data.

Identifiants

pubmed: 33549876
pii: S0731-7085(21)00046-7
doi: 10.1016/j.jpba.2021.113934
pii:
doi:

Substances chimiques

Antiviral Agents 0
Indoles 0
umifenovir 93M09WW4RU

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

113934

Informations de copyright

Copyright © 2021 Elsevier B.V. All rights reserved.

Déclaration de conflit d'intérêts

Declaration of Competing Interest The authors report no declarations of interest.

Auteurs

Philippe-Henri Secretan (PH)

Paris Cardiovascular Research Centre, INSERM U970, Paris, France; Université Paris-Saclay, Matériaux et santé, 92296, Châtenay-Malabry, France. Electronic address: philippe-henri.secretan@universite-paris-saclay.fr.

Hassane Sadou Yayé (H)

Université Paris-Saclay, Matériaux et santé, 92296, Châtenay-Malabry, France; Department of Pharmacy, Pitié-Salpêtrière Hospital, AP-HP, Paris, France.

Audrey Sogaldi (A)

Université Paris-Saclay, Inserm, CNRS, Ingénierie et Plateformes au Service de l'Innovation Thérapeutique, 92296, Châtenay-Malabry, France.

Marie Antignac (M)

Paris Cardiovascular Research Centre, INSERM U970, Paris, France; Department of Pharmacy, Saint-Antoine Hospital, HUEP, AP-HP, Paris, France.

Lionel Tortolano (L)

Université Paris-Saclay, Matériaux et santé, 92296, Châtenay-Malabry, France; Department of Pharmacy, Henri Mondor Hospital, AP-HP, Créteil, France.

Olivier Thirion (O)

Department of Pharmacy, Henri Mondor Hospital, AP-HP, Créteil, France.

Victoire Vieillard (V)

Department of Pharmacy, Henri Mondor Hospital, AP-HP, Créteil, France.

Najet Yagoubi (N)

Université Paris-Saclay, Matériaux et santé, 92296, Châtenay-Malabry, France.

Bernard Do (B)

Université Paris-Saclay, Matériaux et santé, 92296, Châtenay-Malabry, France; Department of Pharmacy, Henri Mondor Hospital, AP-HP, Créteil, France.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH